Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such.
N-Terminally Modified Insulin Derivatives
申请人:Novo Nordisk A/S
公开号:US20140357838A1
公开(公告)日:2014-12-04
The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such.
US9688737B2
申请人:——
公开号:US9688737B2
公开(公告)日:2017-06-27
[EN] NOVEL N-TERMINALLY MODIFIED INSULIN DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'INSULINE À EXTRÉMITÉ N MODIFIÉE
申请人:NOVO NORDISK AS
公开号:WO2012049307A2
公开(公告)日:2012-04-19
The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such.